Study of the Safety and Efficacy of Ulipristal Acetate (UPA) Used Daily as a Contraceptive

PHASE2SuspendedINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

December 31, 2020

Primary Completion Date

January 31, 2022

Study Completion Date

December 31, 2022

Conditions
ContraceptionHealthy Female
Interventions
DRUG

Ulipristal acetate

Ulipristal aceteate 5 mg oral tablets to take two tablets daily.

Trial Locations (18)

10016

New York University, School of Medicine, New York

10032

Columbia University, New York

15213

Univeristy of Pittsburgh School of Medicine, Pittsburgh

19104

University of Pennsylvania Medical Center, Philadelphia

21224

Johns Hopkins Bayview Medical Center, Baltimore

23507

Eastern Virginia Medical School (EVMS), Norfolk

44106

University Hospitals of Cleveland MacDonald Women's Hospital, Cleveland

45267

University of Cincinnati, Cincinnati

60637

University of Chicago, Chicago

80045

University of Colorado, Denver

84106

University of Utah, Salt Lake City

90010

Essential Access, Los Angeles

94110

University of California, San Francisco, San Francisco

95817

University of California, Davis, Sacramento

96826

University of Hawaii, Honolulu

97239

Oregon Health & Science University, Portland

02215

Planned Parenthood League of Massachusetts, Boston

02905

Women & Infants Hospital of Rhode Island, Providence

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

lead

Premier Research

OTHER